Our Company4Tech Inc. is a privately owned medical device company focused on the development of minimally invasive therapies for the treatment of functional tricuspid regurgitation. The company is incorporated in Delaware, USA, with operations in Galway, Ireland. In collaboration with key experts in the Structural Heart field and a combination of over half a century’s worth of experience, 4Tech is dedicated to improving patients’ quality of life through pioneering a clinically advanced technology that offers an alternative solution for physicians and their patients with tricuspid regurgitation. The TriCinch™ System was one of the first transcatheter tricuspid valve repair devices to enter a first in human trial. Preliminary experiences show that the device is a safe, simple and reproducible alternative treatment option for functional tricuspid regurgitation.
Our Board Members
is the Chairman of the Board of Directors of 4Tech Inc since October 2016. He was a Senior Advisor for TPG Capital and Corporate Director of Immucor, Inc. Prior to Immucor, Mr. Hawkins served as Chairman and CEO of Medtronic from 2008 – 1011, which he joined in 2002 as Senior Vice President and President of Medtronic Vascular. Prior to Medtronic, Mr. Hawkins served as President and Chief Executive Officer of Novoste Corp. and held senior leadership positions at American Home Products, Johnson & Johnson, Guidant Corp., and Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.
has served on the Board of Directors of 4Tech Inc since 2011 and served as Chairman from 2011 to 2015. He founded OXO Capital LLC and has been its Chairman since 2007. Mr. Best served as Chief Financial Officer of Boston Scientific Corporation since 1992. He was previously Senior Partner of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. Mr. Best currently serves or has previously served as a Director of Biogen Idec (NASDAQ:BIIB), Haemonetics Corporation (NYSE:HAE), Myriad Genetics (NYSE:MYGN), and numerous privately held, venture-backed life science companies. Mr. Best received a BBA degree from the Kent State University.
MS, MBA has served on the Board of Directors of 4Tech Inc since 2015. Mr. Le Royer served as the Chief Executive Officer and President of Endosense SA (acquired by St Jude Medical in 2013 for total consideration of up to $330 million) until September 2011. He previously worked for Guidant from 1989 to 2004, holding various leadership positions on three continents, including Cardiac Rhythm Management director in Japan, General Manager of the Carotid and Peripheral Business Unit in California, and the European Marketing vice president. Mr. Le Royer received his engineering degree (diplôme d'ingénieur) from the Ecole Supérieure d'Electricité in France, a master's in electrical engineering from the University of Houston, and an MBA degree from Columbia University.
has served on the Board of Directors of 4Tech Inc since 2015. He serves as the Managing Director of Argon CVA, Bio Analytical Research Corporation NV, Biovest CVA, Gengest BVBA. He is a Founder and Managing Director of several clinical reference laboratories, including Fujirebio Europe NV (also known as Innogenetics). He serves or has served as a Director of ActoGeniX, AgroSavfe, Biocartis, deVGen, GENimmune, MDxHealth, Multiplicom, Myoscience, Oystershell, PharmaNeuroBoost, and Quest For Growth. Mr. Mariën holds a Degree in Pharmaceutical Sciences from the State University of Gent.
has served on the Board of Directors of 4Tech Inc since 2015. He is the Founder, Chief Executive Officer, and Chief Investment Officer of Valiance Advisors LLP. Mr. Pensaert previously served as the Chief Executive Officer at La Fayette Investment Management from 2003 to 2007. He previously worked at Lazard in Corporate Finance M&A. Mr. Pensaert holds a BA in Business Economics from the University of Gent, Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille.
has served on the Board of Directors of 4Tech Inc since 2011. He is a Partner at Invus Opportunities, a New York-based private equity firm with a flexible investment mandate and over $1 billion of assets under management. Mr. Tsai joined the firm in 2008 and has led a dozen medtech investments since 2010, serving as a Director or Board Observer in nine of them. Previously, Mr. Tsai was a Case Team Leader at the strategy consulting firm The Monitor Group. He holds an MBA degree from Harvard Business School and a BS degree in Business Administration from the University of Southern California.